Ronald Sánchez-Ávila

Dr. Ronald Sánchez-Ávila

Instituto Universitario Fernández-Vega, Fundación de Investigación Oftalmológica, Universidad de Oviedo, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2017 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
RSRonald Sánchez-Ávila
Ronald Sánchez-Ávila
JMJesús Merayo-Lloves
Jesús Merayo-Lloves
ARAna Cristina Riestra
Ana Cristina Riestra
LCLuis Fernandez-Vega Cueto
Luis Fernandez-Vega Cueto
EAEduardo Anitua
Eduardo Anitua
GOGorka Orive
Gorka Orive

19 July 2021 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
EAEduardo Anitua
Eduardo Anitua
BSBorja De la Sen
Borja De la Sen
GOG Orive
G Orive
RSRonald Sánchez-Ávila
Ronald Sánchez-Ávila
PHP Heredia
P Heredia
JMJesús Merayo-Lloves
Jesús Merayo-Lloves
The use of blood derivatives and especially Plasma rich in growth factors (PRGF), for regenerative purposes has been a common trend along the last decades in the field of oral surgery, dermatology,...

26 December 2018 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
RSRonald Sánchez-Ávila
Ronald Sánchez-Ávila
JMJesús Merayo-Lloves
Jesús Merayo-Lloves
FMFrancisco Muruzabal
Francisco Muruzabal
GOGorka Orive
Gorka Orive
EAEduardo Anitua
Eduardo Anitua
Purpose: To evaluate the efficacy and safety of plasma rich in growth factors eye drops for the treatment of corneal and ocular surface disorders in patients with graft versus host disease. Methods: This retrospective and longitudinal study included graft versus host disease patients with ocular disorders. The resolution of corneal ulcers (area and density staining) was evaluated as primary outcome. Best corrected visual acuity, intraocular pressure, tear film breakup time, Schirmer test, ocular surface disease index, and visual analog score were evaluated as secondary outcomes. All variables were analyzed before and after plasma rich in growth factors treatment. The safety of plasma rich in growth factors treatment was also assessed. Results: Twelve patients (23 eyes) with ocular graft versus host disease were evaluated. Statistically significant improvement in the area (75.7%) and density (73.3%) of the corneal staining, in best corrected visual acuity (74.7%), in ocular surface disease index scale (75.4%), visual analog score frequency (81.4%) and visual analog score severity (81.9%), and an increase of 3.8 s in tear film breakup time and 6 mm in Schirmer test was observed after plasma rich in growth factors treatment (p < 0.001). Some potential modifiers of the therapeutic effect were identified. All patients achieved corneal stability without perforation risk. No adverse events associated with the plasma rich in growth factors were observed. Conclusion: Immunosafe plasma rich in growth factors eye drops for the treatment of patients with ocular graft versus host disease could be safe and effective, showing a high rate of corneal ulcer resolution and dry eye disease control. Plasma rich in growth factors eye drops may help to maintain corneal stability and prevent it against higher ocular complications.

1 April 2018 in Medicine
Verified
Journal Article
Open access
RSRonald Sánchez-Ávila
Ronald Sánchez-Ávila
JMJesús Merayo-Lloves
Jesús Merayo-Lloves
ARAna C Riestra
Ana C Riestra
SBSilvia Berisa
Silvia Berisa
CLCarlos Lisa
Carlos Lisa
EAEduardo Anitua
Eduardo Anitua
To evaluate the safety and efficacy of the surgical use of plasma rich in growth factors fibrin membrane (mPRGF) in different ocular surface pathologies. Fifteen patients with different corneal and conjunctival diseases were included in the study. Patients were grouped according to the use of mPRGF as graft (corneal and/or conjunctival) or dressing; they were also grouped according to the surgical subgroup of intervention (persistent corneal ulcer [PCU], keratoplasty, superficial keratectomy, corneal perforation, and pterygium). Best corrected visual acuity, intraocular pressure (IOP), inflammation control time (ICT), mPRGF AT (PRGF membrane absorption time), and the healing time of the epithelial defect (HTED) were evaluated throughout the clinical follow-up time. Safety assessment was also performed reporting all adverse events. mPRGF showed a total closure of the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients (13.3%). The mean follow-up time was 11.1 ± 4.2 (4.8–22.8) months, the mean ICT was 2.5 ± 1.1 (1.0–4.0) months, the mean mPRGF AT was 12.4 ± 2.0 (10.0–16.0) days, and for the global HTED the mean was 2.9 ± 1.2 (1–4.8) months. Results showed an improvement in BCVA in all patients, with an overall improvement of 2.9 in Vision Lines. The BCVA significantly improved (P < .05) in the groups of corneal graft and dressing. In the PCU subgroup (6 patients), the healing time of epithelial defect was significantly reduced (P < .05) in patients treated only with the mPRGF in comparison to those which mPRGF therapy was associated to the amniotic membrane. The IOP remained stable (P > .05) throughout the clinical follow-up time. No adverse events were reported after mPRGF use. The mPRGF is effective and safe as coadjuvant treatment in surgeries related with ocular surface disorders, being an alternative to the use of amniotic membrane. The mPRGF accelerates tissue regeneration after ocular surface surgery thus minimizing inflammation and fibrosis.

1 May 2018 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
RSRonald Sánchez-Ávila
Ronald Sánchez-Ávila
JMJesús Merayo-Lloves
Jesús Merayo-Lloves
MFMaria Laura Fernandez
Maria Laura Fernandez
LGLuis Alberto Rodríguez Gutiérrez
Luis Alberto Rodríguez Gutiérrez
PRPedro Pablo Rodríguez-Calvo
Pedro Pablo Rodríguez-Calvo
EAEduardo Anitua
Eduardo Anitua
Purpose: To evaluate the efficacy and safety of plasma rich in growth factors (PRGF) eye drops in patients with glaucoma with secondary ocular surface disorders (OSDs) due to surgeries and topical hypotensive drugs use. Materials and methods: A retrospective case-series study design was used including six patients (eight eyes) diagnosed with glaucoma who received surgical (nonpenetrating deep sclerectomy and/or trabeculectomy) and medical treatments (hypotensive eye drops) to control intraocular pressure (IOP) and who developed secondary OSDs, unresponsive to conventional treatments. Patients were treated with PRGF eye drops (four times a day). Outcome measures were ocular surface disease index (OSDI), best-corrected visual acuity (BCVA, in logarithm of the minimum angle of resolution), visual analog scale (VAS), frequency and severity of symptoms, and IOP. The safety of the treatment was also evaluated. Results: Six patients (seven eyes with open-angle glaucoma and one eye with uveitic glaucoma) treated with PRGF eye drops were evaluated. Mean age was 71 years (SD=7.2, range 58–79 years). Five were female and one was male. The mean treatment time was 21.8 weeks (SD=9.0, range 12–36 weeks). The mean time to reach closure of the corneal ulcer was 14.5 (SD=5.5) weeks. A statistical significant reduction in OSDI scale (50.6%), VAS frequency (53.1%), VAS severity (42.0%), and a 41.8% improvement in BCVA were observed (p<0.05). IOP also decreased by 16.6% (p=0.010). Only one of the six patients reported itching in both eyes as an adverse event (AE); however, the patient continued with the PRGF eye drops until the end of therapy; the remaining patients did not report any AEs during the follow-up period. Conclusions: In patients with glaucoma and secondary OSDs refractive to conventional treatments, the treatment with PRGF eye drops could be considered a possible therapeutic option, because it demonstrates an improvement in the signs and symptoms of the ocular surface, as well as a better control of the IOP. This is an initial research work that can open doors for future research to confirm these findings.

7 February 2023 in Current Eye Research
Verified
Journal Article
Closed access
EAEduardo Anitua
Eduardo Anitua
MFMaría de la Fuente
María de la Fuente
RSRonald Sánchez-Ávila
Ronald Sánchez-Ávila
BSBorja De la Sen
Borja De la Sen
JMJesús Merayo-Lloves
Jesús Merayo-Lloves
FMFrancisco Muruzabal
Francisco Muruzabal
In the last few decades, several blood derived products such as platelet-rich plasma (PRP), plasma rich in growth factors (PRGF) and autologous serum (AS) have been used for the treatment of ocular...